Zobrazeno 1 - 10
of 272
pro vyhledávání: '"Paul W H I Parren"'
Autor:
Rob N de Jong, Frank J Beurskens, Sandra Verploegen, Kristin Strumane, Muriel D van Kampen, Marleen Voorhorst, Wendy Horstman, Patrick J Engelberts, Simone C Oostindie, Guanbo Wang, Albert J R Heck, Janine Schuurman, Paul W H I Parren
Publikováno v:
PLoS Biology, Vol 14, Iss 1, p e1002344 (2016)
IgG antibodies can organize into ordered hexamers on cell surfaces after binding their antigen. These hexamers bind the first component of complement C1 inducing complement-dependent target cell killing. Here, we translated this natural concept into
Externí odkaz:
https://doaj.org/article/bfabba60d9884594bbcd39074b399b29
Autor:
Nannie Bangsgaard, Mischa Houtkamp, Danita H Schuurhuis, Paul W H I Parren, Ole Baadsgaard, Hans W M Niessen, Lone Skov
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39706 (2012)
Epidermal growth factor receptor (EGFR) inhibitors are widely used in the treatment of cancer. EGFR-targeted treatment is known to be associated with a high incidence of dermatological adverse reactions, including papulopustular rash, which can be do
Externí odkaz:
https://doaj.org/article/a7bf7bf6a0564bfba7c3d87f5a9e1d0b
Autor:
Sean X Du, Li Xu, Wenge Zhang, Susan Tang, Rebecca I Boenig, Helen Chen, Ellaine B Mariano, Michael B Zwick, Paul W H I Parren, Dennis R Burton, Terri Wrin, Christos J Petropoulos, John A Ballantyne, Michael Chambers, Robert G Whalen
Publikováno v:
PLoS ONE, Vol 6, Iss 6, p e20927 (2011)
A prophylactic vaccine is needed to slow the spread of HIV-1 infection. Optimization of the wild-type envelope glycoproteins to create immunogens that can elicit effective neutralizing antibodies is a high priority. Starting with ten genes encoding s
Externí odkaz:
https://doaj.org/article/8aeb5bb4d0ea428fa8ca3ec1ac121e60
Autor:
Magdalena Winiarska, Jacek Bil, Ewa Wilczek, Grzegorz M Wilczynski, Malgorzata Lekka, Patrick J Engelberts, Wendy J M Mackus, Elzbieta Gorska, Lukasz Bojarski, Tomasz Stoklosa, Dominika Nowis, Zuzanna Kurzaj, Marcin Makowski, Eliza Glodkowska, Tadeusz Issat, Piotr Mrowka, Witold Lasek, Anna Dabrowska-Iwanicka, Grzegorz W Basak, Maria Wasik, Krzysztof Warzocha, Maciej Sinski, Zbigniew Gaciong, Marek Jakobisiak, Paul W H I Parren, Jakub Golab
Publikováno v:
PLoS Medicine, Vol 5, Iss 3, p e64 (2008)
BackgroundRituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis
Externí odkaz:
https://doaj.org/article/8a6f737eb02e4bb2b26604dc216cc95b
Autor:
Wendelien B Oswald, Thomas W Geisbert, Kelly J Davis, Joan B Geisbert, Nancy J Sullivan, Peter B Jahrling, Paul W H I Parren, Dennis R Burton
Publikováno v:
PLoS Pathogens, Vol 3, Iss 1, p e9 (2007)
Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the neutralizing human monoclonal antibody, KZ52, to protec
Externí odkaz:
https://doaj.org/article/2636594cdf7b4e28bea0a562c2f32757
Autor:
Haiyu Wang, Fleur S. van de Bovenkamp, Douwe J. Dijkstra, Leoni Abendstein, Nicole V. Borggreven, Jos Pool, Rob Zuijderduijn, Christoph Gstöttner, Kyra A. Gelderman, Timon Damelang, Gestur Vidarsson, Anna M. Blom, Elena Domínguez-Vega, Paul W. H. I. Parren, Thomas H. Sharp, Leendert A. Trouw
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Complement activation protects against infection but also contributes to pathological mechanisms in a range of clinical conditions such as autoimmune diseases and transplant rejection. Complement-inhibitory drugs, either approved or in development, u
Externí odkaz:
https://doaj.org/article/66693f5931e04cbdb02cb3b635c4eb80
Autor:
Willemijn van der Wulp, Anna M. Gram, Boris Bleijlevens, Renate S. Hagedoorn, Can Araman, Robbert Q. Kim, Jan Wouter Drijfhout, Paul W. H. I. Parren, Richard G. Hibbert, Rob C. Hoeben, Sander I. van Kasteren, Janine Schuurman, Maaike E. Ressing, Mirjam H. M. Heemskerk
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Therapeutic antibody-epitope conjugates (AECs) are promising new modalities to deliver immunogenic epitopes and redirect virus-specific T-cell activity to cancer cells. Nevertheless, many aspects of these antibody conjugates require optimization to i
Externí odkaz:
https://doaj.org/article/458e15a064ab40b08049bc6f97a6578d
Autor:
Simone C. Oostindie, Hilma J. van der Horst, Margaret A. Lindorfer, Erika M. Cook, Jillian C. Tupitza, Clive S. Zent, Richard Burack, Karl R. VanDerMeid, Kristin Strumane, Martine E. D. Chamuleau, Tuna Mutis, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Frank J. Beurskens, Paul W. H. I. Parren, Ronald P. Taylor
Publikováno v:
Haematologica, Vol 104, Iss 9 (2019)
CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natura
Externí odkaz:
https://doaj.org/article/8951ab20ead14f0a871191432d4962ce
Publikováno v:
Nature Reviews Drug Discovery, 21(10), 715-735. NATURE PORTFOLIO
Antibody function is dependent on avidity - the accumulated strength of multiple affinity interactions between the antibody, antigen, cell surface receptors and other antibodies. In this Review, Oostindie et al. discuss the role of avidity in eliciti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4da7678cb248273fc8dd627179fde8b
https://doi.org/10.1038/s41573-022-00501-8
https://doi.org/10.1038/s41573-022-00501-8
Autor:
Iris de Weerdt, Tanja D. de Gruijl, Jurjen M Ruben, Hans van Vliet, Mark-David Levin, Lisa A King, Roeland Lameris, Arnon P. Kater, Paul W. H. I. Parren, Renate de Boer, Jan Kloosterman
Publikováno v:
de Weerdt, I, Lameris, R, Ruben, J M, de Boer, R, Kloosterman, J, King, L A, Levin, M-D, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 6, pp. 1744-1755 . https://doi.org/10.1158/1078-0432.CCR-20-4576
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Purpose: Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c3e81ce4a42d0051944a87497c4687f
https://doi.org/10.1158/1078-0432.ccr-20-4576
https://doi.org/10.1158/1078-0432.ccr-20-4576